TOP HEADLINES

FEATURED STORY

Vical posts herpes vaccine PhI/II failure, gutting shares

After suffering a Phase III immunotherapy flop in 2013 and restructuring, Vical delivered another piece of damaging news on Monday that sent the company's shares into penny stock territory.

MERS getting more attention as vaccine candidate enters PhI

As the MERS outbreak in South Korea continues to unfold, scientists at Ludwig Maximilian University of Munich are ushering a candidate vaccine into clinical trials with hopes of a winner.

HIV vaccine research a 'major advance,' NIH official says

After publishing promising preclinical results, a team from the Scripps Research Institute, led by researcher William Schief, are taking their HIV vaccine candidate to federal regulators to discuss human trials.

NIH grants Northeastern prof $1.4M to address 'bottleneck' in vaccine development

The National Institutes of Health has awarded Northeastern professor of chemical engineering Shashi Murthy a four-year $1.4 million grant to develop a novel instrument that would ease a "tremendous bottleneck" in vaccine development.

Ebola vaccines left hanging as GSK, Merck, J&J scramble for trial volunteers

The race for an Ebola vaccine has slowed to a crawl as Big Pharmas GlaxoSmithKline, Merck and Johnson & Johnson struggle to find volunteers who are exposed to enough disease to show whether experimental vaccines actually protect against Ebola infection.

MORE NEWS

From Our Sister Sites

FiercePharma Manufacturing

Consultants tell Reuters that large Indian companies are heeding the warnings from regulators and investing more in equipment and training. But some small to medium-sized companies are considering whether to pour money into their operations, retreat from high-profit but regulatory-heavy markets like the U.S. and Europe, or cash out.

FiercePharma Manufacturing

India's Dr. Reddy's Laboratories is having to recall both an epilepsy drug and a combo cardiovascular drug all made in India. One, the FDA says, is too strong while the other is not strong enough. The recalls come even as the FDA has been paying special attention to generic equivalence after testing has found evidence that some generics are not measuring up.